Hofseth BioCare ASA (HOFBF) Income Statement Analysis

See more : Route Mobile Limited (ROUTE.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Hofseth BioCare ASA (HOFBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hofseth BioCare ASA, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

cMoney, Inc. (CMEY) Income Statement Analysis – Financial Results
Sichuan Shudao Equipment & Technology Co.,Ltd. (300540.SZ) Income Statement Analysis – Financial Results
Clover Biopharmaceuticals, Ltd. (2197.HK) Income Statement Analysis – Financial Results
Shanghai Tianyong Engineering Co., Ltd. (603895.SS) Income Statement Analysis – Financial Results
EGR Exploration Ltd. (CDNMF) Income Statement Analysis – Financial Results

Hofseth BioCare ASA (HOFBF)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.hofsethbiocare.no

About Hofseth BioCare ASA

Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	194.87M	120.45M	87.62M	69.25M	67.78M	60.74M	118.48M	20.20M	55.14M	19.77M	62.94M	26.02M	1.18M	171.00K
Cost of Revenue	150.69M	91.93M	64.52M	39.53M	59.57M	48.36M	54.93M	101.41M	65.37M	14.62M	25.31M	23.96M	462.00K	0.00
Gross Profit	44.19M	28.51M	23.10M	29.72M	8.21M	12.38M	63.55M	-81.21M	-10.24M	5.15M	37.62M	2.05M	721.00K	171.00K
Gross Profit Ratio	22.67%	23.67%	26.36%	42.92%	12.11%	20.38%	53.64%	-401.93%	-18.56%	26.05%	59.78%	7.89%	60.95%	100.00%
Research & Development	11.01M	13.64M	12.53M	7.56M	131.00K	2.43M	1.30M	1.79M	4.38M	2.82M	1.69M	0.00	0.00	0.00
General & Administrative	21.99M	17.87M	31.82M	18.67M	8.02M	5.54M	5.64M	7.33M	9.64M	10.19M	12.57M	11.60M	0.00	0.00
Selling & Marketing	13.49M	15.04M	13.03M	7.86M	4.30M	2.23M	754.00K	1.81M	2.74M	1.34M	957.00K	1.37M	0.00	0.00
SG&A	65.48M	32.91M	44.85M	26.54M	12.32M	7.76M	6.40M	9.14M	12.39M	11.53M	13.53M	12.96M	0.00	0.00
Other Expenses	70.22M	1.56M	0.00	-86.00K	-8.93M	0.00	-777.00K	-892.00K	-1.22M	0.00	0.00	0.00	0.00	0.00
Operating Expenses	146.72M	157.13M	141.66M	121.83M	88.56M	90.86M	75.52M	64.25M	84.33M	69.56M	86.57M	60.10M	25.04M	13.08M
Cost & Expenses	297.40M	249.07M	206.18M	161.36M	148.13M	139.22M	130.45M	165.66M	149.70M	84.18M	111.88M	84.06M	25.50M	13.08M
Interest Income	550.00K	651.00K	613.00K	553.00K	510.00K	209.00K	100.00K	381.00K	47.00K	42.00K	30.00K	59.00K	102.00K	-3.00K
Interest Expense	7.54M	9.95M	9.39M	9.22M	8.57M	3.83M	3.32M	10.35M	9.39M	7.07M	5.63M	5.06M	1.44M	131.00K
Depreciation & Amortization	36.41M	30.22M	29.35M	23.81M	25.15M	22.19M	21.70M	18.57M	18.59M	14.05M	12.56M	7.91M	1.66M	-76.00K
EBITDA	-62.73M	-97.01M	-85.57M	-68.28M	-55.49M	-58.51M	8.54M	-118.54M	-74.28M	-44.60M	-32.52M	-50.02M	-22.62M	-12.83M
EBITDA Ratio	-32.19%	-80.55%	-100.12%	-95.68%	-78.77%	-94.09%	7.20%	-570.20%	-130.99%	-212.46%	-56.44%	-192.28%	-1,825.36%	-7,502.34%
Operating Income	-102.53M	-128.62M	-118.57M	-92.02M	-79.57M	-77.70M	-11.20M	-144.56M	-93.35M	-63.22M	-47.49M	-58.04M	-24.32M	-12.91M
Operating Income Ratio	-52.61%	-106.78%	-135.32%	-132.88%	-117.40%	-127.92%	-9.45%	-715.52%	-169.30%	-319.78%	-75.45%	-223.12%	-2,055.71%	-7,546.78%
Total Other Income/Expenses	-4.16M	-8.77M	-7.90M	-10.07M	-9.64M	-6.83M	-5.29M	-2.90M	-6.86M	-3.72M	-4.68M	-4.95M	-1.40M	-134.00K
Income Before Tax	-106.68M	-137.39M	-126.46M	-102.09M	-89.22M	-84.53M	-16.48M	-147.46M	-100.20M	-66.94M	-52.17M	-63.00M	-25.71M	-13.04M
Income Before Tax Ratio	-54.75%	-114.07%	-144.34%	-147.42%	-131.63%	-139.16%	-13.91%	-729.85%	-181.73%	-338.61%	-82.89%	-242.15%	-2,173.63%	-7,625.15%
Income Tax Expense	0.00	1.18M	1.49M	-1.01M	-1.28M	249.00K	-1.97M	3.25M	2.52M	7.14M	-631.00K	11.53M	-6.68M	-3.65M
Net Income	-106.68M	-137.39M	-126.46M	-102.09M	-89.21M	-84.77M	-16.48M	-147.45M	-100.19M	-66.92M	-52.14M	-73.86M	-19.04M	-9.39M
Net Income Ratio	-54.74%	-114.06%	-144.34%	-147.42%	-131.62%	-139.56%	-13.91%	-729.81%	-181.72%	-338.50%	-82.84%	-283.91%	-1,609.13%	-5,489.47%
EPS	-0.27	-0.37	-0.35	-0.31	-0.29	-0.33	-0.07	-1.01	-0.95	-0.73	-0.72	-1.29	-0.45	-0.33
EPS Diluted	-0.27	-0.37	-0.35	-0.31	-0.29	-0.33	-0.07	-1.01	-0.94	-0.72	-0.70	-1.25	-0.43	-0.33
Weighted Avg Shares Out	395.08M	374.74M	357.83M	333.65M	307.29M	258.99M	234.31M	146.19M	105.62M	91.39M	72.66M	57.36M	42.76M	28.33M
Weighted Avg Shares Out (Dil)	395.08M	374.74M	357.83M	333.65M	307.29M	258.99M	234.31M	146.64M	107.05M	92.72M	74.42M	59.09M	44.17M	28.43M

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

February 5, 2021globenewswire.com

Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA (“HBC”), has today purchased 70,000 shares in HBC at an average price of NOK 9.294 per share.

Hofseth Biocare ASA: Boosts Sales & Marketing in its Consumer Health division by hiring ex-Novartis and ex-GSK senior executive Andy Gill

November 30, 2020globenewswire.com

HBC is delighted to announce the hiring of Andy Gill as VP within HBC's Consumer Health Division from January 2021. Mr Gill is a highly accomplished commercial leader with over 20 years' experience in driving growth in the Healthcare and...